Oncotarget

Research Papers:

The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma

Qi Ling, Xiao Xu, Panpan Ye, Haiyang Xie, Feng Gao, Qichao Hu, Zhikun Liu, Xuyong Wei, Christian Röder, Anna Trauzold, Holger Kalthoff and Shusen Zheng _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:15159-15167. https://doi.org/10.18632/oncotarget.14768

Metrics: PDF 1826 views  |   HTML 2710 views  |   ?  


Abstract

Qi Ling1,2,*, Xiao Xu1,2,*, Panpan Ye3,*, Haiyang Xie1,2, Feng Gao1,2, Qichao Hu2, Zhikun Liu1,2, Xuyong Wei1,2, Christian Röder4, Anna Trauzold4, Holger Kalthoff4, Shusen Zheng1,2

1Department of Surgery, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

2Key Laboratory of Combined Multi-Organ Transplantation, Ministry of Public Health, China

3The Ophthalmology Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China

4Institute for Experimental Cancer Research, Comprehensive Cancer Center North, CAU, Kiel, Germany

*These authors contributed equally to this work

Correspondence to:

Shusen Zheng, email: [email protected]

Holger Kalthoff, email: [email protected]

Keywords: anatomy, microRNA, pancreatic cancer, recurrence

Received: January 22, 2016     Accepted: January 10, 2017     Published: January 20, 2017

ABSTRACT

Different clinical presentations and prognoses have been implied between pancreatic head and body/tail cancers. We aimed to identify the prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma (PDAC). Thirty-two pairs of patients with strictly matched early stage (II) pancreatic head and body/tail cancers were enrolled. The molecular feature of the two subtypes of PDAC was assessed on the level of miRNA expression. Out of the 64 patients, 34 (53.1%) had tumor recurrence after radical resection during the follow-up period (2.3 ± 0.8 years). Both overall and tumor-free survival were significantly higher in the patients with pancreatic body/tail cancer compared with those with pancreatic head cancer. Patient age and tumor location were the independent prognostic factors for tumor recurrence. A remarkably lower expression of miR-501-3p and higher expression of miR-375 were found and were further verified in pancreatic body/tail cancer tissues compared with pancreatic head cancer tissues. The low expression of miR-501-3p was significantly associated with a low risk of tumor recurrence. Both, subcutaneous and orthotopic PDAC mouse models presented highly invasive tumor phenotypes upon up-regulated miR-501-3p expression. An in vitro study showed that miR-501-3p promoted the invasiveness of PDAC cells possibly via suppressing E-cadherin. In summary, at resectable early stage, pancreatic body/tail cancer presents a less malignant phenotype associated with deregulation of miR-501-3p compared with pancreatic head cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14768